scholarly journals Glucose tolerance and insulin responsiveness in Gitelman syndrome patients

2017 ◽  
Vol 6 (4) ◽  
pp. 243-252 ◽  
Author(s):  
Tao Yuan ◽  
Lanping Jiang ◽  
Chen Chen ◽  
Xiaoyan Peng ◽  
Min Nie ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Insulin Sensitivity ◽  
Glucose Metabolism ◽  
Healthy Subjects ◽  
Potassium Level ◽  
Serum Glucose ◽  
Oral Glucose ◽  
Oral Glucose Load ◽  
Glucose Load

Objective Impaired glucose metabolism and insulin sensitivity have been reported in patients with Gitelman syndrome (GS), but insulin secretion and the related mechanisms are not well understood. Design and methods The serum glucose levels, insulin secretion and insulin sensitivity were evaluated in patients with GS (n = 28), patients with type 2 diabetes mellitus (DM) and healthy individuals (n = 20 in both groups) using an oral glucose tolerance test. Serum and urine sodium, potassium and creatinine levels were measured at 0, 30, 60, 120 and 180 min after an oral glucose load was administered. Results The areas under the serum glucose curves were higher in the GS patients than those in the healthy controls (17.4 ± 5.1 mmol·h/L vs 14.5 ± 2.8 mmol·h/L, P = 0.02) but lower than those in the DM patients (24.8 ± 5.3 mmol·h/L, P < 0.001). The areas under the serum insulin curves and the insulin secretion indexes in GS patients were higher than those in DM patients and lower than those in healthy subjects. The insulin secretion-sensitivity index of GS patients was between that of healthy subjects and DM patients, but the insulin sensitivity indices were not different among the three groups. After one hour of glucose administration, the serum potassium level significantly decreased from baseline, and the urinary potassium-to-creatinine ratio increased gradually and peaked at 2 h. Conclusions Glucose metabolism and insulin secretion were impaired in GS patients, but insulin sensitivity was comparable between GS patients and patients with type 2 DM. After administration of an oral glucose load, the plasma potassium level decreased in GS patients due to the increased excretion of potassium in the urine.

scholarly journals Pharmacological studies of Neopicrorrhiza scrophularii-flora and its antidiabetic effect

2015 ◽  
Vol 27 (1) ◽  
pp. 34-39
Author(s):  
Nayan Manandhar
Keyword(s):  
Water Extract ◽  
Serum Glucose ◽  
Control Group ◽  
Active Principle ◽  
Oral Glucose ◽  
Oral Glucose Load ◽  
Glucose Load ◽  
Animal House ◽  
Type 2 Diabetic

Neopicrorrhiza srophulariiflora (NS), locally known as “kutki / katuki” in nepali is available in 3500-4800 m of Nepal. The present study was carried out to evaluate the antidiabetic property of NS in streptozotocin (STZ) induced type 2 diabetic model rats. NS dried rhizomes, was extracted with 80% ethanol and water by cold percolation method. The extracts were administered at a dose of 1.25gkg-1 body weight for 21 consecutive days to type 2 diabetic male Long-Evans rats, bred at BIRDEM animal house. Serum glucose was estimated by GOD PAP method. Ethanol extract of N. srophulariiflora significantly (p<0.05) improved oral glucose tolerance in type 2 rats in comparison to control group. The water extract and ethanol extracts significantly lowered serum glucose level of type 2 diabetic rats in both prandial states (simultaneously with oral glucose load p<0.05; at 75min and 30 minutes prior to oral glucose load p<0.05; at 105min) compared to control group. N. srophulariiflora is beneficial for treating Type 2 diabetes and therefore needs further exploration and researches, both chemically and biologically to identify the active principle(s) and mechanism of action. DOI: http://dx.doi.org/10.3126/jnpa.v27i1.12148 Journal of Nepal Pharmaceutical Association 2014 Vol.XXVII: 34-39

scholarly journals Lean mass inversely predicts plasma glucose levels after oral glucose load independent of insulin secretion or insulin sensitivity in glucose intolerance subjects

2014 ◽  
Vol 61 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Jirateep Kwankaew ◽  
Sunee Saetung ◽  
Suwannee Chanprasertyothin ◽  
Rattana Leelawattana ◽  
Chatchalit Rattarasarn
Keyword(s):  
Insulin Secretion ◽  
Insulin Sensitivity ◽  
Glucose Intolerance ◽  
Lean Mass ◽  
Plasma Glucose ◽  
Oral Glucose ◽  
Oral Glucose Load ◽  
Glucose Load ◽  
Glucose Levels

The disposal of an oral glucose load in healthy subjects. A quantitative study

Diabetes ◽  
1985 ◽  
Vol 34 (6) ◽  
pp. 580-588 ◽  
Author(s):  
E. Ferrannini ◽  
O. Bjorkman ◽  
G. A. Reichard ◽  
A. Pilo ◽  
M. Olsson ◽  
...  
Keyword(s):  
Quantitative Study ◽  
Healthy Subjects ◽  
Oral Glucose ◽  
Oral Glucose Load ◽  
Glucose Load

GLP-1 and GIP Levels in Patients With Hyperthyroidism: The Effect of Antithyroid Treatment

2017 ◽  
Vol 51 (8) ◽  
pp. 663-668
Author(s):  
Duygu Kalkan Cira ◽  
Ramazan Sari ◽  
Sebahat Ozdem ◽  
Nusret Yilmaz ◽  
Selen Bozkurt
Keyword(s):  
Gastric Inhibitory Polypeptide ◽  
Tolerance Test ◽  
Serum Glucose ◽  
Oral Glucose ◽  
Oral Glucose Load ◽  
Glucose Load ◽  
Time To Peak ◽  
Euthyroid State ◽  
Antithyroid Treatment ◽  
Glucagon Like Peptide 1

Background:Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism. Objective: We aimed to assess both incretin levels and treatment-induced changes in incretin levels in those with hyperthyroidism. Methods: A total of 24 subjects (12 with hyperthyroidism and 12 healthy) were enrolled in the study. Oral glucose tolerance test was performed and serum glucose, insulin GLP1, and GIP levels were evaluated at 0 (baseline), 30, 60, 90, and 120 minutes using ELISA. Measurements were repeated after euthyroidism was reached in subjects with hyperthyroidism. Results: The baseline glucose level was higher in those with hyperthyroidism compared with controls ( P = 0.03). GLP-1 and GIP responses to oral glucose load did not differ significantly between those with hyperthyroidism and controls. Peak GLP-1 and GIP levels were reached in both groups at 60 and 90 minutes, respectively. Areas under the curve (AUCs) for GLP1 and GIP were similar in those with hyperthyroidism and controls. Although GLP-1 and GIP levels did not change before and after antithyroid treatment in subjects with hyperthyroidism, time to peak GLP-1 and GIP levels were reached at 30 minutes after euthyroid state was achieved. Reversal of hyperthyroid to euthyroid status did not induce significant changes in AUCs for incretins. Conclusion: The findings of the present study suggest that the total incretin response to oral glucose load is preserved in patients with hypertyhroidism, but peak incretin responses may change after achieving euthyroid state.

Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects

2011 ◽  
Vol 74 (2) ◽  
pp. 234-240 ◽  
Author(s):  
Annamaria Colao ◽  
Rosario Pivonello ◽  
Renata S. Auriemma ◽  
Ludovica F. S. Grasso ◽  
Mariano Galdiero ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Waist Circumference ◽  
Healthy Subjects ◽  
Normative Data ◽  
Oral Glucose ◽  
Oral Glucose Load ◽  
Glucose Load ◽  
Gender And Age

scholarly journals Plasma FGF-21 and Sclerostin Levels, Glycemia, Adiposity and Insulin Sensitivity in Normoglycemic Black and White Adults

2021 ◽  
Author(s):  
Nkiru Umekwe ◽  
Ibiye Owei ◽  
Frankie Stentz ◽  
Sam Dagogo-Jack
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Insulin Secretion ◽  
Insulin Sensitivity ◽  
Healthy Subjects ◽  
Fibroblast Growth ◽  
Black And White ◽  
Fasting Plasma ◽  
White Adults

Abstract Increased circulating fibroblast growth factor (FGF)-21 and sclerostin levels have been reported in patients with type 2 diabetes (T2D). We assessed the association of FGF-21 and sclerostin with adiposity, glycemia and glucoregulatory measures in healthy subjects. We studied 20 normoglycemic Black and White offspring of parents with T2D. Assessments included OGTT, insulin sensitivity (Si-clamp), insulin secretion (HOMA-B), and body fat (DXA). Fasting plasma FGF-21 and sclerostin levels were measured with ELISAs. The participants' mean (+SD) age was 50.4 ± 5.97 yr; BMI 32.5 ± 5.86 kg/m2; fasting plasma glucose (FPG) 96.1 ± 5.21 mg/dl, and 2-hr post-load glucose (2hPG) 116 ± 5.45 mg/dl. FGF-21 levels were similar in Blacks vs. Whites (0.36 ± 0.15 ng/ml vs. 0.39 ± 0.25 ng/ml), men vs. women (0.45 ± 0.14 vs. 0.44 ± 0.07ng/ml), correlated positively with body mass index (BMI) (r=0.23, P=0.05) and waist circumference (r=0.27, P=0.04), and inversely with FPG (r= -0.26, P=0.05). Sclerostin levels also were similar in Blacks (33.5 ± 17.1 pmol/l) vs. Whites (34.2 ± 6.41 pmol/l), men vs. women (35.3 ± 9.01 pmol/l vs. 32.3 ± 15.8 pmol/l), and correlated inversely with FPG (r= - 0.11-0.44) but not adiposity measures. The correlation coefficient between Si-clamp values and FGF-21 levels was -0.31 (P=0.09) compared with 0.04 (P=0.89) for sclerostin levels. FGF-21 and sclerostin levels were not correlated with each other or HOMA-B. Among healthy Black and White subjects, plasma FGF-21 and sclerostin showed differential associations with adiposity but concordant association with FPG levels.

Sign in / Sign up

Export Citation Format

Share Document